TDSGFTelo Genomics Corp.

About Telo Genomics Corp. (TDSGF)

Telo Genomics Corp. (TDSGF) is a Diagnostics & Research company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQB tier.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

Products and services

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

TDSGF key facts

Ticker symbol

TDSGF

Market tier

OTCQB

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2014

Employees

9

Estimated market cap

$5.69M (as of May 14, 2025)

Shares outstanding

100,018,933

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Interim Financial Report (Dec 31, 2024)

Telo Genomics Corp. leadership

• Sherif Louis — President, Corporate Secretary, CTO
• Dr. Sabine Mai — Interim CEO
• Chris Ross — CFO
• Monita Franziska Faris — Corporate Secretary
• Victoria Bantz — Other

Explore more: Diagnostics & Research stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with T